Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers - Wikidata - awgldk - TriplyDB

Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers

Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers

http://www.wikidata.org/entity/Q39347810

about

Ligand-Independent EGFR Signaling Targeting molecular addictions in cancer Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM.Target validation using chemical probes.Glial progenitors as targets for transformation in glioma.A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastoma Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.CNS Anticancer Drug Discovery and Development Conference White Paper.InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.Mechanisms of resistance to EGFR targeted therapies.Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.Quantitating cell-cell interaction functions with applications to glioblastoma multiforme cancer cells.An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?Drug-Target Kinetics in Drug Discovery.Occupy EGFR.Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling.DRR regulates AKT activation to drive brain cancer invasion.A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.

P2860

Q26797495-370CACEA-50AB-44A1-8FB9-69133A10269C Q26829525-375AAB8A-D0B7-43C0-B9AD-3C5B09039270 Q27674725-28EFCB30-5F98-42B6-81C5-9F7E84B88204 Q30652283-41E9EFD8-9893-49FC-919D-780AF1E5FE7E Q33923431-DB8AECC7-0878-4EBD-BE5C-8172F0680470 Q34333826-FFE47E70-7AA6-4039-999B-0F5E0124F8BD Q34735661-DB47D00D-4FFF-4DB9-8F39-AFC333D0C35A Q35162374-B19CDFA2-3744-4C9E-A465-9F162858CE79 Q35612289-9208F4FF-8AB7-4908-9B61-69C1B2B997EA Q36089590-1B243AB0-946B-484E-9B03-743347960E48 Q36759183-25ECD3CE-3CD9-4481-8281-B1A998357E80 Q36887721-7911CB2F-0956-49C7-9886-41F3FEABBAF3 Q36891085-241978EE-B085-4280-A780-BB37B5D7D217 Q36923052-79E674B5-EF98-4EF0-B53C-0342952D6280 Q37672593-525FF8BE-F3B5-41FF-AF52-DA447E2F28A2 Q38199643-E8A8CAD7-6E15-4E3A-B894-5874F88FF725 Q38364234-B9051CB3-8458-4862-A731-ABFFA64F8DC8 Q39391104-9A44F3F1-7FF1-4D70-AE98-2EBDC3FB5539 Q41976220-679761B5-F581-4FDD-801D-8F75D21E513B Q42418384-6789E07D-043A-4288-B7FE-1D398CBCF20F Q45412782-FF23F975-98D3-4558-AEE7-09962638DB4B Q46093038-4005AB52-026A-4F62-8023-778494D9E1EA Q50100856-B38A4817-5253-4C3C-A50A-ED2ADC1AA786

P2860

Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers

http://www.wikidata.org/entity/Q39347810

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Kinetics of inhibitor cycling ...... -driven lung and brain cancers

@en

Kinetics of inhibitor cycling ...... driven lung and brain cancers.

@nl

type

label

Kinetics of inhibitor cycling ...... -driven lung and brain cancers

@en

Kinetics of inhibitor cycling ...... driven lung and brain cancers.

@nl

prefLabel

Kinetics of inhibitor cycling ...... -driven lung and brain cancers

@en

Kinetics of inhibitor cycling ...... driven lung and brain cancers.

@nl

P1433

Q39347810-5A2714E2-EB67-453C-8AF3-E6D04621A1AF

P1476

Q39347810-A1B25EDD-F618-4998-B4F8-08C1434A373B

P2093

Q39347810-09D7938B-7FDD-48AF-BCFF-8B97FABBB036

Q39347810-0FB631C9-CBEC-4CF1-9DF2-D9BA1410F7FD

Q39347810-11B7E661-9C3D-4E72-A4B4-CD465E8DD2B7

Q39347810-1C330773-0C10-4FA1-A738-3CA64EDBBE79

Q39347810-B0908652-DCEB-4500-A7D9-BEBBC7144951

Q39347810-B4E0FBBC-3C1D-41DD-B145-B809AACB3E39

Q39347810-E3725C5B-3F4B-4CBB-829E-18AE0B655562

P2860

Q39347810-005AAB20-3EC4-480F-82DA-43F51DEB32D5

Q39347810-00AD9967-F3BD-44B0-93A2-4FF0E8B7E8FC

Q39347810-171EB1B4-AED0-4C58-A230-9251324C65CF

Q39347810-20E061A2-667D-45B9-A614-69FD57D759CA

Q39347810-2A53D246-8D87-43CE-8ECA-A4C589D2C698

Q39347810-39EE0835-AA55-4E6B-A39C-FC3C10331599

Q39347810-47501A45-EAEF-4503-8D1E-F6980C770B03

Q39347810-4B407AF7-F1E1-40AA-AA8D-8C5D39C119AC

Q39347810-5327EE18-FE55-4760-A5FD-A066C7DFD13A

Q39347810-64706051-DC04-4416-9B1E-24ACC64D414A

P304

Q39347810-1397656E-64D8-42A4-87AE-43B7B4EEC5C9

P31

Q39347810-626FBBD4-34D5-4941-8D70-4D9A2848E521

P356

Q39347810-AB04DF72-DA93-40B3-BA38-735C3C023144

P433

Q39347810-24E9A2DD-CDA3-4A90-819C-E9503F85FD89

P478

Q39347810-66460E4D-383E-48CA-8737-78F2BD01061C

P50

Q39347810-2899E0FE-2A60-48B1-AF61-0FDB6C748E66

Q39347810-84AF0411-F372-464A-9439-610DA3358C32

P577

Q39347810-C116410E-D817-47DA-BF4A-414F8400A11E

P698

Q39347810-84498751-13F1-4E31-AFC3-5A9E9B46D32F

P932

Q39347810-5D68CB27-8C44-44D4-A043-0EEFF013E75B

P356

2159-8290.CD-11-0287

P1433

Cancer Discovery

P1476

Kinetics of inhibitor cycling ...... -driven lung and brain cancers

@en

P2093

Adam L Garske

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Jimmy A Blair

http://www.w3.org/2001/XMLSchema#string

Kevan M Shokat

http://www.w3.org/2001/XMLSchema#string

Krister J Barkovich

http://www.w3.org/2001/XMLSchema#string

Qi-Wen Fan

http://www.w3.org/2001/XMLSchema#string

Sujatmi Hariono

http://www.w3.org/2001/XMLSchema#string

P2860

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

EGFR antagonists in cancer treatment

Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

P304

450-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-11-0287

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

William A Weiss

Theodore P Nicolaides

P577

2012-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22588882

http://www.w3.org/2001/XMLSchema#string

P932

3354705

http://www.w3.org/2001/XMLSchema#string